Fresenius Kabi faced FDA warning while Jefferies kept Buy on Fresenius stock

Published on 10/08/2026 at 12:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached EUR 5.864 billion, up 6.00 percent year over year. Fresenius stock costs EUR 41.50 on October 8, 2026 after EUR 43.25.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock was at EUR 41.50 at Lang & Schwarz on October 8, 2026 at 12:31 p.m. CEST, down 4.05 percent versus its prior close. Fresenius Kabi had faced an FDA warning letter dated September 22, 2026, while Jefferies had kept a Buy rating on Fresenius stock with a EUR 55.00 target, according to FDA Watch and FinanzNachrichten.

FDA warning raises quality risk

The FDA letter cited inadequate investigations, aseptic processing weaknesses and visual inspection deficiencies at Fresenius Kabi's Melrose Park, Illinois, sterile injectable facility, as FDA Watch reported on October 8, 2026. The letter also covered recalls involving three famotidine injection batches and six additional injectable batches, putting quality remediation beside Fresenius Kabi's growth agenda.

For investors, the issue is operational rather than purely financial: unresolved manufacturing findings can affect product approvals, government contracts and export certificates. The warning therefore adds a measurable execution risk to a business that remains central to Fresenius's medical-products strategy.

Quarterly growth remained broad

Fresenius reported Q2 2026 revenue of EUR 5.864 billion, up 6.00 percent year over year, and operating profit of EUR 719.00 million, up 10.00 percent, on its investor-relations page dated August 5, 2026, Fresenius reported. Core net income increased 14.00 percent to EUR 470.00 million, while core earnings per share rose 14.00 percent to EUR 0.83 in the same quarter.

The segment mix supports that comparison: Fresenius Kabi revenue grew 7.00 percent to EUR 2.244 billion in Q2 2026, while Helios revenue increased 5.00 percent to EUR 3.526 billion, according to Fresenius. The FDA warning is consequently set against a quarter in which both major operating divisions delivered year-over-year growth.

Analyst target stays above price

Jefferies had maintained a Buy rating and a EUR 55.00 price target in a note dated October 2, 2026, according to FinanzNachrichten. The target lies 32.53 percent above the EUR 41.50 Lang & Schwarz price, leaving the analyst view focused on biosimilars, medical technology and nutrition despite the manufacturing risk.

Stock trades below prior close

Fresenius stock was trading at EUR 41.50 at Lang & Schwarz on October 8, 2026 at 12:31 p.m. CEST, down 4.05 percent versus the Lang & Schwarz prior close of EUR 43.25 on October 7, 2026. The next reported quarterly financial report is scheduled for November 4, 2026, according to the Fresenius financial calendar.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.